Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1830 1
1885 1
1953 1
1964 1
1967 1
1980 2
1981 2
1982 3
1983 5
1984 6
1985 5
1986 4
1987 8
1988 9
1989 3
1990 5
1991 16
1992 10
1993 5
1994 22
1995 18
1996 17
1997 25
1998 20
1999 27
2000 25
2001 27
2002 26
2003 16
2004 21
2005 36
2006 29
2007 38
2008 25
2009 37
2010 38
2011 24
2012 44
2013 46
2014 53
2015 57
2016 48
2017 58
2018 75
2019 95
2020 107
2021 91
2022 108
2023 95

Text availability

Article attribute

Article type

Publication date

Search Results

1,279 results

Results by year

Filters applied: . Clear all
Page 1
Nonalcoholic Fatty Liver Disease in Children.
Mann JP, Valenti L, Scorletti E, Byrne CD, Nobili V. Mann JP, et al. Among authors: byrne cd. Semin Liver Dis. 2018 Feb;38(1):1-13. doi: 10.1055/s-0038-1627456. Epub 2018 Feb 22. Semin Liver Dis. 2018. PMID: 29471561 Free article. Review.
Non-alcoholic fatty liver disease and childhood obesity.
Shaunak M, Byrne CD, Davis N, Afolabi P, Faust SN, Davies JH. Shaunak M, et al. Among authors: byrne cd. Arch Dis Child. 2021 Jan;106(1):3-8. doi: 10.1136/archdischild-2019-318063. Epub 2020 May 14. Arch Dis Child. 2021. PMID: 32409495 Review.
Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review.
Mantovani A, Byrne CD, Targher G. Mantovani A, et al. Among authors: byrne cd. Lancet Gastroenterol Hepatol. 2022 Apr;7(4):367-378. doi: 10.1016/S2468-1253(21)00261-2. Epub 2022 Jan 12. Lancet Gastroenterol Hepatol. 2022. PMID: 35030323 Review.
MAFLD and risk of CKD.
Sun DQ, Jin Y, Wang TY, Zheng KI, Rios RS, Zhang HY, Targher G, Byrne CD, Yuan WJ, Zheng MH. Sun DQ, et al. Among authors: byrne cd. Metabolism. 2021 Feb;115:154433. doi: 10.1016/j.metabol.2020.154433. Epub 2020 Nov 16. Metabolism. 2021. PMID: 33212070
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, Arrese M, Bataller R, Beuers U, Boursier J, Bugianesi E, Byrne CD, Narro GEC, Chowdhury A, Cortez-Pinto H, Cryer DR, Cusi K, El-Kassas M, Klein S, Eskridge W, Fan J, Gawrieh S, Guy CD, Harrison SA, Kim SU, Koot BG, Korenjak M, Kowdley KV, Lacaille F, Loomba R, Mitchell-Thain R, Morgan TR, Powell EE, Roden M, Romero-Gómez M, Silva M, Singh SP, Sookoian SC, Spearman CW, Tiniakos D, Valenti L, Vos MB, Wong VW, Xanthakos S, Yilmaz Y, Younossi Z, Hobbs A, Villota-Rivas M, Newsome PN; NAFLD Nomenclature consensus group. Rinella ME, et al. Among authors: byrne cd. Ann Hepatol. 2023 Jun 24;29(1):101133. doi: 10.1016/j.aohep.2023.101133. Online ahead of print. Ann Hepatol. 2023. PMID: 37364816 Free article. Review.
1,279 results